

Paragraph IV Patent Certifications

June 5, 2017

The PDF contains a list of drug products for which an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification. This list includes the name of the drug product, dosage form, strength (subject of Paragraph IV certification), reference listed drug (RLD), and the date on which the first substantially complete generic drug application was submitted to the Agency (on a prospective basis beginning 3/2/2004). The Agency will not disclose the identity of the applicant. This information will be updated twice a month and will be as current as the last update. This information should be used for reference only. The Agency will make every effort to ensure the accuracy of the information disclosed in this list. However, any discrepancies or disparities should be discussed with the Division of Filing Review at 240-402-8859 (<http://sharepoint.fda.gov/orqs/CDER-OCOMM-DOC/CDERWebSupport/Lists/WebSupportCDER/Item/displayifs.aspx?List=61607bdc%2D5465%2D4f84%2Da459%2Df2a5edf81b3d&ID=1162&Web=3b7d4fca%2De6cb%2D4c79%2D87a0%2D791df4a9610#>), before making any decisions based on this information.

DRUG NAME	DOSAGE FORM	STRENGTH	RLD	DATE OF SUBMISSION
Canagliflozin	Tablets	100 mg and 300 mg	Invokana	3/29/2017
Canagliflozin and Metformin Hydrochloride	Tablets	50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, and 150 mg/1000 mg	Invokamet	3/29/2017
Dimethyl Fumarate	Delayed-release Capsules	120 mg and 240 mg	Tecfidera	3/27/2017
Meloxicam	Capsules	5 mg and 10 mg	Vivlodex	1/9/2017

Related Information

- [Paragraph IV Patent Certifications \(PPIV\) \(PDF - 429KB\) \(/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf\)](#)

Resources for You

- [Office of Generic Drugs \(/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm119100.htm\)](#)
- [Approved Drug Products with Therapeutic Equivalence Evaluations \(Orange Book\) \(/Drugs/InformationOnDrugs/ucm129662.htm\)](#)
- [First Generic Drug Approvals \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ANDAGenericDrugApprovals/default.htm\)](#)

More in Abbreviated New Drug Application (ANDA): Generics
 (/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm)

[Generic Drugs: Information for Industry \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm142112.htm\)](#)

[Abbreviated New Drug Application \(ANDA\) Forms and Submission Requirements \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm120955.htm\)](#)

[Activities Report of the Generic Drug Program \(FY 2017\) \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm375079.htm\)](#)

▶ [Paragraph IV Patent Certifications \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm047676.htm\)](#)

[Suitability Petitions \(/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm120944.htm\)](#)

